Validation of the English Version of the Drug Hypersensitivity Quality of Life Questionnaire

We aim to validate the English (UK) translation of the DrHy-Q, and test its reliability in the UK population. This will facilitate for the subsequent economical evaluation of penicillin allergy delabelling.

This research project is part of an MSc in Allergy undertaken by the principal applicant, Dr Patricia Romero, supervised through Imperial College London.

Target population are patients with a drug allergy diagnosed by an Allergist prospectively at the Drug Allergy Clinic.

Is the English version of the Drug Hypersensitivity Quality of Life Questionnaire suitable to be used in the UK population?

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Drug Hypersensitivity Chemically-Induced Disorders Drug-Related Side Effects and Adverse Reactions Quality of Life

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

UNiversity Hospitals Leicester

Leicester, LE39QP, United Kingdom

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

• Age >18 years

Ability to read English and consent.
Confirmed diagnosis of a drug hypersensitivity reaction.
Written informed consent

Exclusion criteria

• < 18y/o.

Not able to read English. No mental capacity to consent or unwilling to consent.
Unconfirmed diagnosis of a drug hypersensitivity reaction.

Treatment and study plan

questionnaires

Other

No intervention

Primary outcomes

Validation of the English version of the Drug Hypersensitivity Questionnaire

Time frame: March 2023 May 2024

Reliability and validity

Sponsors and collaborators

Lead sponsor

University Hospitals, Leicester

Other

Registry information

Official study title

The English Version of the Drug Hypersensitivity Quality of Life Questionnaire: Validity and Reliability in the British Population.

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Jul 26, 2024
Registry last updated: Jul 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed